Efficacy of Gilteritinib targeted drug

Gilteritinib (Gilteritinib) is a targeted therapy drug that has shown significant efficacy in clinical trials, especially in the treatment of certain hematological malignancies. This article will provide an in-depth discussion of the pharmacological effects, clinical trial results, and prospects of giritinib in the treatment of leukemia.

Leukemia is a hematological malignancy caused by the uncontrolled proliferation of abnormal cells in the bone marrow. Among them, FLT3 gene mutations are relatively common in patients with acute myeloid leukemia (AML), accounting for about 30% of cases. FLT3Gene mutations lead to abnormal activation of FLT3 receptor tyrosine kinase, thereby stimulating the growth and differentiation of leukemia cells. Giritinib is a targeted drug targeting FLT3 gene mutation and has been widely studied and used for the treatment of AML.

Giritinib blocks the growth and differentiation of leukemia cells by inhibiting the activity ofFLT3 receptor tyrosine kinase. It is highly selective and mainly targets two different types of FLT3 mutations: FLT3-ITD and FLT3-TKD. The FLT3-ITD mutation is an FLT3 internal repeat mutation, while the FLT3-TKD mutation involves the tyrosine kinase domain of FLT3. The high selectivity of giritinib makes it an effective tool for treating both FLT3 mutations.

Clinical trials of giritinib have shown encouraging efficacy in multiple studies. Here are some important clinical trial results:

1. RATIFYTest

The RATIFY trial, a pivotal clinical trial in AML patients, confirmed the efficacy of giritinib. The results of the study showed that compared with standard chemotherapy regimens, giritinib significantly prolonged the progression-free survival of patients with FLT3-ITD mutations (median progression-free survival, mPFS), and improved overall survival. This discovery provides new hope for the treatment of AML patients.

2. ADMIRALTest

The ADMIRALtrial focuses on the treatment of AML patients with FLT3-TKD mutations. The trial results showed that giritinib also achieved significant efficacy in this subgroup. After patients receive giritinib treatment, the disease remission rate is high and the patient's survival is expected to be prolonged.

3. Treatment of Relapse/RefractoryAML

Giritinib is also used for the treatment of relapsed/refractory AML (relapsed/refractory AML). Conventional therapies often have limited efficacy in these patients, but clinical trials of giritinib have shown its potential to improve survival prospects in these patients. This provides new treatment options for patients whose disease relapses or is difficult to treat.

Side Effects and Safety:

While giritinib works well inAML, it can cause some side effects, including nausea, vomiting, fatigue, and low platelet counts. During treatment, patients require regular monitoring to ensure timely management of side effects.

Giritinib, as a targeted therapy drug targeting FLT3 gene mutations, provides new treatment opportunities for leukemia patients. It has achieved significant clinical trial results in the first-line treatment of AML and in the treatment of relapsed/refractory AML. In the future, giritinib may further improveAMLThe prognosis of patients, and may become one of the standard therapies in the treatment ofAML.

Giritinib is currently on the market in China, but it is not included in medical insurance. If patients need it, they can go to the hospital to buy it at their own expense, but the price is very high, about about 35,000 yuan. For specific prices, please consult the local hospital pharmacy. Foreign original drugs of gilitinib are even more expensive. For example, the price of the Hong Kong version of the original drug is around 90,000 yuan, and the European version of the original drug is as high as more than 200,000 yuan, which is simply unaffordable for ordinary patients. There are already foreign generic drugs of Giritinib on the market, mainly Laos generic drugs. The price is about 4,000 to 5,000 yuan, which is relatively cheap. In terms of drug ingredients, the ingredients of domestic and foreign original gilitinib drugs are basically the same as those of generic drugs.